IgA Nephropathy: What's New?

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2007 Jul 11

PMID 17619908

Citations 1

Authors

Ronald J Hogg

Affiliations

Soon will be listed here.

Abstract

Although IgA nephropathy has only been recognized as a definitive entity for fewer than 40 years, its place in the world as a prominent cause for progressive kidney disease is well established. The extent to which we understand the role of genetically derived abnormal forms of the IgA molecule in the disease is evolving, and this will, hopefully, translate into more specific modes of treatment for patients in the future. In the meantime, we have few specific therapeutic options, most of which have not been well studied in large numbers of patients. The extent to which we can define which patients are likely to progress--and hence should be considered candidates for treatment--will be discussed in this Commentary. In addition, the notion that some patients may have reached "the point of no return" will also be addressed. Unfortunately, most of the comments will be based on results obtained in studies conducted in adults--a situation that is very familiar to pediatric nephrologists.

Citing Articles

Outcome results in children with IgA nephropathy: a single center experience.

Bulut I, Mir S, Sozeri B, Bulut M, Sen S, Dincel N Int J Nephrol Renovasc Dis. 2012; 5:23-8.

PMID: 22334797 PMC: 3278251. DOI: 10.2147/IJNRD.S24684.

References

Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E . Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003; 14(6):1578-83. DOI: 10.1097/01.asn.0000068460.37369.dc. View

Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R . IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007; 18(6):1880-8. DOI: 10.1681/ASN.2006040347. View

Chen X, Chen P, Cai G, Wu J, Cui Y, Zhang Y . [A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy]. Zhonghua Yi Xue Za Zhi. 2002; 82(12):796-801. View

Lee Y, Baek S, Kim J, Kim D, Lee J, Kim P . Analysis of renal biopsies performed in children with abnormal findings in urinary mass screening. Acta Paediatr. 2006; 95(7):849-53. DOI: 10.1080/08035250600652005. View

Song J, Lee S, Suh J, Kim E, Hong S, Kim K . The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol. 2003; 60(5):318-26. DOI: 10.5414/cnp60318. View

Kam-Tao Li P, Leung C, Chow K, Cheng Y, Ka-Shun Fung S, Mak S . Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006; 47(5):751-60. DOI: 10.1053/j.ajkd.2006.01.017. View

Amore A, Cirina P, Conti G, Brusa P, Peruzzi L, Coppo R . Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol. 2001; 12(9):1862-1871. DOI: 10.1681/ASN.V1291862. View

. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114(2 Suppl 4th Report):555-76. View

Tumlin J, Hennigar R . Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol. 2004; 24(3):256-68. DOI: 10.1016/j.semnephrol.2004.01.006. View

10.

Gesualdo L, Di Palma A, Morrone L, Strippoli G, Schena F . The Italian experience of the national registry of renal biopsies. Kidney Int. 2004; 66(3):890-4. DOI: 10.1111/j.1523-1755.2004.00831.x. View

11.

Hogg R, Fitzgibbons L, Atkins C, Nardelli N, Bay R . Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent. Clin J Am Soc Nephrol. 2007; 1(6):1167-72. DOI: 10.2215/CJN.02300606. View

12.

Li G, Zhang H, Lv J, Shen Y, Wang H . Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int. 2007; 71(5):448-53. DOI: 10.1038/sj.ki.5002088. View

13.

Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi G, Altieri P . Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2003; 15(1):157-63. DOI: 10.1097/01.asn.0000103869.08096.4f. View

14.

Donadio J, Bergstralh E, Bibus D, Grande J . Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?. Clin J Am Soc Nephrol. 2007; 1(5):933-9. DOI: 10.2215/CJN.00260106. View

15.

Simon P, Ramee M, Boulahrouz R, Stanescu C, Charasse C, Ang K . Epidemiologic data of primary glomerular diseases in western France. Kidney Int. 2004; 66(3):905-8. DOI: 10.1111/j.1523-1755.2004.00834.x. View

16.

Rivera F, Lopez-Gomez J, Perez-Garcia R . Clinicopathologic correlations of renal pathology in Spain. Kidney Int. 2004; 66(3):898-904. DOI: 10.1111/j.1523-1755.2004.00833.x. View

17.

DAmico G . Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004; 24(3):179-96. DOI: 10.1016/j.semnephrol.2004.01.001. View

18.

Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Yanase T . Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis. 2003; 41(5):972-83. DOI: 10.1016/s0272-6386(03)00194-x. View

19.

Frisch G, Lin J, Rosenstock J, Markowitz G, DAgati V, Radhakrishnan J . Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005; 20(10):2139-45. DOI: 10.1093/ndt/gfh974. View

20.

Myllymaki J, Honkanen T, Syrjanen J, Helin H, Rantala I, Pasternack A . Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant. 2004; 20(1):89-95. DOI: 10.1093/ndt/gfh584. View